Study guide

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding

Nutritionist-Dietitian Licensure Examination NDLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Licensure Law, Ethics, and the Clinical Nutritionist-Dietitian

1.1 NDLE Format, Scoring Rules, and RA 10862 Licensure Requirements 1.2 Scope of Practice, Professional Ethics, and Discipline under RA 10862 1.3 Role of the Clinical Nutritionist-Dietitian, Diet Orders, and Standard Hospital Diets

2 Chapter 2: Anatomy and Physiology for Nutrition I

2.1 Cells, Tissues, Membranes, and the Immune and Lymphatic Systems 2.2 The Digestive System: Organs, Enzymes, GI Hormones, and the Liver 2.3 Endocrine and Nervous System Regulation of Metabolism and Appetite

3 Chapter 3: Anatomy and Physiology II, Energy, and Carbohydrate Metabolism

3.1 Cardiovascular, Respiratory, Renal, Musculoskeletal, and Reproductive Systems 3.2 Energy Metabolism and Energy Expenditure Calculations 3.3 Carbohydrate Chemistry, Digestion, and Glycemic Pathways

4 Chapter 4: Protein, Lipid, Mineral, and Fluid Biochemistry

4.1 Protein Chemistry, Amino Acid Metabolism, and Nitrogen Balance 4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers 4.3 Minerals, Water, Electrolytes, and Acid-Base Balance

5 Chapter 5: Basic Nutrition: Vitamins, Minerals, and the PDRI

5.1 Vitamin Biochemistry: Coenzyme Functions and Deficiency Syndromes 5.2 Vitamins and Minerals: PDRI Values, Food Sources, Bioavailability, Stability, and Toxicity 5.3 Philippine Dietary Reference Intakes (PDRI 2015), Pinggang Pinoy, and Dietary Guidelines

6 Chapter 6: Diet Computation and Clinical Nutrition Assessment

6.1 Food Exchange Lists, Meal Plan Computation, Food Labels, and Nutrient Density 6.2 Computing Desirable Body Weight, Total Energy Requirement, and the Diet Prescription 6.3 ABCD Methods of Clinical Nutrition Assessment

7 Chapter 7: Nutrition Diagnosis, Life-Stage Assessment, and Laboratory Data

7.1 Nutrition Diagnosis, PES Statements, and Medical Record Documentation 7.2 Pediatric, Obstetric, and Geriatric Clinical Nutritional Assessment 7.3 Interpreting Biochemical and Laboratory Data in Nutrition Assessment

8 Chapter 8: Drug-Nutrient Interactions, Diabetes, and Weight Disorders

8.1 Drug-Nutrient Interactions and Nutrient Depletion 8.2 MNT for Diabetes Mellitus and Endocrine Disorders 8.3 MNT for Overweight, Obesity, and Underweight

9 Chapter 9: MNT for Cardiovascular, Renal, and Gastrointestinal Disease

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia 9.2 MNT for Renal Diseases (AKI, CKD Stages 1-5, Dialysis, and Nephrotic Syndrome) 9.3 MNT for Disorders of the Gastrointestinal Tract

10 Chapter 10: MNT for Liver, Infectious, Respiratory, Allergic, and Neurologic Conditions

10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders 10.2 MNT for Fevers, Infections, Diarrheal Disease, and Respiratory Disorders 10.3 MNT for Food Allergy and Intolerance, Skin, Rheumatic, Musculoskeletal, and Neurologic Disorders

11 Chapter 11: Critical Illness, Oncology, HIV, and Protein-Energy Malnutrition

11.1 MNT in Critical Illness, Sepsis, Trauma, and Burns 11.2 MNT in Oncology: Cancer Cachexia and Treatment Side Effects 11.3 MNT for HIV/AIDS and for Protein-Energy Malnutrition in Children and Adults

12 Chapter 12: Metabolic Disorders, Dysphagia, and Enteral Nutrition

12.1 MNT for Inborn Errors of Metabolism and Eating Disorders 12.2 Dysphagia, IDDSI Texture-Modified Diets, and Adaptive Feeding 12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

13 Chapter 13: Parenteral Nutrition, Refeeding, and Nutrition Counseling

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding 13.2 Refeeding Syndrome and Complications of Parenteral Nutrition 13.3 Nutrition Counseling and Behavior Change Theories

14 Chapter 14: Nutrition Updates: Supplements, Diet Trends, and Sports Nutrition

14.1 Dietary Supplements, Herbal Medicines, and Functional Foods 14.2 Vegetarian Diets, Protein Complementation, and Popular Diet Trends 14.3 Sports Nutrition and Workplace Wellness Programs

15 Chapter 15: Community Nutrition and Population Assessment

15.1 Community Nutrition Principles, the ND's Roles, and the Philippine Health Delivery System 15.2 Nutritional Epidemiology and Health Status Indicators in the Philippines 15.3 Assessment of Community Nutritional Status and Operation Timbang Plus (OPT+)

16 Chapter 16: Dietary Surveys, Nutrition Research, and Surveillance

16.1 Food Consumption Surveys, Biochemical Tests in Surveys, and Clinical Signs of Deficiency 16.2 Food and Nutrition Research Methods, Sampling, Sample Size, and Research Ethics 16.3 National Nutrition Surveys, Demographic Data, and Designing a Nutrition Surveillance System

17 Chapter 17: Nutrition Education and Program Evaluation

17.1 Nutrition Education: Definition, Principles of Learning, Methods, and Teaching Aids 17.2 Designing a Nutrition Education Program and Measuring Customer Satisfaction 17.3 Program Planning Cycle, SMART Objectives, and Types of Evaluation

18 Chapter 18: Program Planning, Interventions, and Food Security

18.1 Nutrition Program Planning: Needs, Priorities, Constraints, Goals, and Using Evaluation Results 18.2 Nutrition Interventions and Programs for Specific Population Groups 18.3 Food and Nutrition Security, Dietary Diversity, and Vulnerable Populations

19 Chapter 19: Nutrition Governance, Networking, and Program History

19.1 National Nutrition Council (NNC) Structure and Philippine Plan of Action for Nutrition (PPAN) 19.2 Nutrition Agencies, Networking, Community Linkages, Teamwork, and Nutrition Legislation 19.3 Development of Philippine Nutrition Programs and the Country's Nutrition Problems

20 Chapter 20: Fortification, Feeding, and First 1,000 Days Laws

20.1 Food Fortification (RA 8976), Salt Iodization (RA 8172), and the 2024 Salt Industry Law 20.2 Supplementary Feeding Programs (RA 11037) and DSWD/DepEd Interventions 20.3 First 1,000 Days Law (RA 11148) and Maternal-Child Interventions

21 Chapter 21: Nutrition in the Life Cycle I

21.1 Infant and Young Child Feeding (IYCF), Philippine Milk Code (EO 51), and RA 10028 21.2 Nutrition in Pregnancy and Lactation: Physiology, Needs, Meal Patterns, and Problems 21.3 Nutrition from Infancy to School Age: Growth, Feeding Patterns, Problems, and School Programs

22 Chapter 22: Nutrition in the Life Cycle II

22.1 Nutrition for Adolescents and Adults: Growth Spurt, Risk Factors, and NCD Prevention 22.2 Nutrition for Older Adults: Aging Changes, Needs, Problems, and Senior Citizen Programs

23 Chapter 23: Food Science and Plant Foods

23.1 Chemistry of Starches, Proteins, Lipids, and Emulsions in Cooking 23.2 Food Pigments, Flavor Chemistry, and Browning Reactions (Maillard & Enzymatic) 23.3 Fruits, Vegetables, and Legumes: Classification, Market Forms, Quality, Storage, and Cookery

24 Chapter 24: Animal Foods, Cereals and Baking, and Cooking Methods

24.1 Meat, Poultry, Fish, Eggs, and Milk: Structure, Quality, Storage, and Cookery 24.2 Cereals, Flour Mixtures and Baking, Sugar Cookery, Fats and Oils, and Beverages 24.3 Heat Transfer, Dry-Heat and Moist-Heat Cooking Methods, and Filipino Cooking Techniques

25 Chapter 25: Culinary Skills, Family Meal Planning, and Food Quality

25.1 Culinary Vocabulary, Knife Cuts, Basic Sauces, and Accurate Measurement 25.2 Meal Planning for the Family, Food Budgeting, and Recipe Development 25.3 Sensory Evaluation, Objective Food Tests, and Quality Assurance in Food Production

26 Chapter 26: Food Microbiology, Preservation, and Food Law

26.1 Foodborne Pathogens, Microbial Kinetics, and FAT TOM Parameters 26.2 Food Preservation Methods, Thermal Processing, and Packaging 26.3 Philippine Food Laws, Regulatory Agencies, and Food Labeling

27 Chapter 27: Sanitation, HACCP, Waste, and Workplace Safety

27.1 Sanitation Standard Operating Procedures (SSOP) and Good Manufacturing Practices (GMP) 27.2 HACCP Principles and Critical Control Point Management in Food Service 27.3 Waste Management, Pest Control Regulation, and Occupational Safety in Food Service

28 Chapter 28: Food Service Systems, Production Planning, and Menus

28.1 Types of Food Service Delivery Systems (Conventional, Ready-Prepared, Commissary, Assembly) 28.2 Forecasting, Production Planning, and Quantity Food Production Techniques 28.3 Institutional Menu Planning, Modified Diets, and Recipe Standardization

29 Chapter 29: Distribution, Purchasing, and Storage

29.1 Food Distribution and Service Systems in Hospitals and Other Institutions 29.2 Food Purchasing Methods, Specifications, and Receiving 29.3 Storage Management, Inventory Control, and Valuation

30 Chapter 30: Cost Control, Financial Management, and Facility Layout

30.1 Food Cost Accounting, Yield Testing, and Portion Control Formulas 30.2 Menu Pricing Models, Break-Even Analysis, and Financial Statements 30.3 Food Service Facility Layout, Equipment Selection, and Workflow Ergonomics

31 Chapter 31: Equipment, Management, and Human Resources

31.1 Food Service Equipment: Selection, Capacity, Life-Cycle Cost, Depreciation, and Maintenance 31.2 Management Functions, Theories, Leadership Styles, and Managing Change in Food Service 31.3 Human Resource Management: Job Design, Recruitment, Training, Appraisal, and Discipline

32 Chapter 32: Labor Law, Permits, and Food Service Marketing

32.1 Philippine Labor Laws and Business Permits for Food Service Operations 32.2 Food Service Marketing, Menu Engineering, and Sustainable Food Service

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding

Key Takeaways Explain This Topic AI

Parenteral Nutrition (PN) is indicated strictly when the gastrointestinal tract is non-functional, inaccessible, or perforated, including prolonged paralytic ileus (>5–7 days), high-output enterocutaneous fistulae (>500 mL/day), severe short bowel syndrome, or intractable malabsorption.

Peripheral Parenteral Nutrition (PPN) is restricted to a strict osmolarity ceiling of ≤ 900 mOsm/L \le 900\text{ mOsm/L} ≤ 900 mOsm/L and dextrose concentrations ≤ 10 % \le 10\% ≤ 10% to prevent thrombophlebitis, whereas Central Parenteral Nutrition (TPN) via the superior vena cava accommodates hypertonic admixtures (>900 to 2,000+ mOsm/L).

Parenteral dextrose monohydrate yields 3.4 kcal/g; clinical compounding must respect the maximum Glucose Infusion Rate (GIR) of 4 to 5 mg/kg/min in critically ill adults to prevent hepatic steatosis, hyperglycemia, and hypercapnia.

Lipid emulsions provide about 1.1 kcal/mL (10%), 2.0 kcal/mL (20%), and 3.0 kcal/mL (30%); fat-free parenteral nutrition can cause essential fatty acid deficiency within 1-3 weeks.

Last updated: October 2026

Parenteral Nutrition (PN) is the intravenous administration of essential nutrients—including dextrose, crystalline amino acids, intravenous lipid emulsions (IVLE), electrolytes, vitamins, and trace elements—directly into the systemic circulation, bypassing the gastrointestinal tract entirely. In the Nutritionist-Dietitian Licensure Examination (NDLE) , clinical candidates must demonstrate absolute mastery of PN indications, vascular access osmolarity thresholds, macronutrient calculations, compounding stability, the life-threatening dynamics of Refeeding Syndrome , and long-term metabolic monitoring.

Indications and Clinical Criteria for Parenteral Nutrition

Parenteral nutrition is a complex, high-cost, and invasive medical therapy. It should be reserved exclusively for patients in whom the gastrointestinal tract is non-functional, perforated, or inaccessible:

Clinical Indications

Non-Functional Gastrointestinal Tract: Prolonged paralytic ileus ( > 5 to 7 days >5\text{ to }7\text{ days} > 5 to 7 days ), complete mechanical intestinal obstruction where surgical bypass is not feasible, or generalized diffuse peritonitis.

Severe Short Bowel Syndrome: Massive intestinal resection resulting in intestinal failure ( < 100 cm <100\text{ cm} < 100 cm remaining small bowel without colon, or < 60 cm <60\text{ cm} < 60 cm with colon).

High-Output Enterocutaneous Fistula: Enterocutaneous fistula output exceeding 500 mL/day 500\text{ mL/day} 500 mL/day , where feeding access distal to the fistula cannot be achieved.

Intractable Gastrointestinal Disorders: Severe intractable vomiting or diarrhea unresponsive to medical therapies, severe malabsorption syndromes, severe graft-versus-host disease (GVHD) of the gut, or severe mesenteric ischemia.

Failed Enteral Nutrition in Critical Illness: Critically ill patients who fail to tolerate post-pyloric enteral nutrition or whose enteral intake remains < 60 % <60\% < 60% of estimated requirements after 7 to 10 days of hospitalization.

Contraindications

A functional, accessible gastrointestinal tract capable of absorbing adequate nutrients.

Anticipated duration of therapy < 5 days <5\text{ days} < 5 days in a previously well-nourished patient.

Inability to obtain safe vascular access.

Palliative settings where PN is contrary to advance directives or the patient's goals of care.

Severe active hemodynamic instability, severe uncorrected electrolyte/acid-base derangements, or pulmonary edema (correct prior to initiating PN).

Peripheral Parenteral Nutrition (PPN) vs. Central Parenteral Nutrition (TPN)

The fundamental determinant distinguishing peripheral from central parenteral nutrition is the osmolarity of the solution , which dictates the required vascular diameter and blood flow velocity. Vascular Access Determination

  • │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • [Peripheral Access: PPN] [Central Access: TPN / CPN]
  • Cephalic / basilic veins - Superior Vena Cava (SVC)
  • Osmolarity CEILING: <= 900 mOsm/L - Accommodates >900 to 2,000+ mOsm/L
  • Dextrose limit: <= 10% (D10W) - Concentrated dextrose (20%–70% stock)
  • Large volume required (2.5–3.5 L/day) - Fluid-restricted friendly (1–1.5 L/day)
  • Short-term support (<10–14 days) - Long-term support (weeks, months, years)
  • Risk: Chemical thrombophlebitis - Risk: Central line infections (CRBSI)
  • Comparison of PPN and Central TPN

Clinical Parameter Peripheral Parenteral Nutrition (PPN) Central Parenteral Nutrition (TPN / CPN)

Venous Insertion Site Small peripheral veins of forearm (cephalic, basilic) Subclavian, internal jugular, or PICC line

Catheter Tip Location Peripheral subcutaneous vein Distal Superior Vena Cava (SVC) at the cavoatrial junction

Venous Blood Flow Low flow ( 25 – 50 mL/min 25–50\text{ mL/min} 25–50 mL/min ) Massive high-velocity flow ( 2,000 – 2,500 mL/min 2{,}000–2{,}500\text{ mL/min} 2 , 000–2 , 500 mL/min )

Maximum Osmolarity ≤ 900 mOsm/L \le 900\text{ mOsm/L} ≤ 900 mOsm/L (absolute ceiling) No osmolarity limit ( > 900 to 2,000 + mOsm/L >900\text{ to }2{,}000+\text{ mOsm/L} > 900 to 2 , 000 + mOsm/L )

Dextrose Concentration Maximum ≤ 10 % \le 10\% ≤ 10% ( 100 g/L 100\text{ g/L} 100 g/L ) Concentrated: 15 % to 35 % 15\%\text{ to }35\% 15% to 35% in final bag

Amino Acid Concentration Typically 2.5 % to 5 % 2.5\%\text{ to }5\% 2.5% to 5% 5 % to 10 + % 5\%\text{ to }10+\% 5% to 10 + % in final bag

Fluid Volume Required Large ( 2.5 to 3.5 + L/day 2.5\text{ to }3.5+\text{ L/day} 2.5 to 3.5 + L/day ) to meet calories Concentrated ( 1.0 to 2.0 L/day 1.0\text{ to }2.0\text{ L/day} 1.0 to 2.0 L/day )

Therapy Duration Strictly short-term ( < 10 to 14 days <10\text{ to }14\text{ days} < 10 to 14 days ) Long-term ( > 14 days >14\text{ days} > 14 days to years/lifetime)

Candidate Suitability Mild-moderate stress, normal fluid tolerance Fluid-restricted (renal, CHF), severe catabolism

  • Primary Complication Chemical thrombophlebitis and vein loss Catheter-Related Bloodstream Infection (CRBSI)
  • Calculating Solution Osmolarity

To ensure a proposed peripheral PN admixture does not exceed the 900 mOsm/L 900\text{ mOsm/L} 900 mOsm/L safety ceiling, use standard osmolar coefficients:

Estimated Osmolarity (mOsm/L) = [ g Dextrose/L × 5 ] + [ g Amino Acids/L × 10 ] + [ mEq Total Electrolytes/L × 2 ] + [ g Lipid/L × 0.7 ] \text{Estimated Osmolarity (mOsm/L)} = [\text{g Dextrose/L} \times 5] + [\text{g Amino Acids/L} \times 10] + [\text{mEq Total Electrolytes/L} \times 2] + [\text{g Lipid/L} \times 0.7] Estimated Osmolarity (mOsm/L) = [ g Dextrose/L × 5 ] + [ g Amino Acids/L × 10 ] + [ mEq Total Electrolytes/L × 2 ] + [ g Lipid/L × 0.7 ]

Clinical Example: A 1-liter peripheral solution containing 100 g dextrose, 40 g amino acids, and 100 mEq total electrolytes: Osmolarity = ( 100 × 5 ) + ( 40 × 10 ) + ( 100 × 2 ) = 500 + 400 + 200 = 1,100 mOsm/L \text{Osmolarity} = (100 \times 5) + (40 \times 10) + (100 \times 2) = 500 + 400 + 200 = 1{,}100\text{ mOsm/L} Osmolarity = ( 100 × 5 ) + ( 40 × 10 ) + ( 100 × 2 ) = 500 + 400 + 200 = 1 , 100 mOsm/L Because 1,100 mOsm/L > 900 mOsm/L 1{,}100\text{ mOsm/L} > 900\text{ mOsm/L} 1 , 100 mOsm/L > 900 mOsm/L , this admixture cannot be infused peripherally and requires central venous access.

  • Parenteral Macronutrient Energetics and Compounding Parenteral Macronutrient Substrates
  • │
  • ┌─────────────────────────────┼─────────────────────────────┐
  • ▼ ▼ ▼
  • [Dextrose Monohydrate] [Crystalline Amino Acids] [Intravenous Lipid Emulsion]
  • 3.4 kcal/gram - 4.0 kcal/gram - 10% IVLE = 1.1 kcal/mL
  • Hydrated monosaccharide - L-amino acid crystalline mix - 20% IVLE = 2.0 kcal/mL
  • Min: 100–150 g/day - Protein / 6.25 = Nitrogen - 30% IVLE = 3.0 kcal/mL
  • MAX GIR: 4–5 mg/kg/min - NPC:N ratio calculations - Soy vs. SMOF emulsion
  • 1. Carbohydrates: Dextrose Monohydrate

Energetic Density: In parenteral nutrition, dextrose is supplied as dextrose monohydrate (each D-glucose molecule crystallizes with one water molecule). Therefore, parenteral dextrose yields 3.4 kcal/g 3.4\text{ kcal/g} 3.4 kcal/g , unlike anhydrous dietary carbohydrate which yields 4.0 kcal/g 4.0\text{ kcal/g} 4.0 kcal/g .

Minimum Requirement: At least 100 to 150 g/day 100\text{ to }150\text{ g/day} 100 to 150 g/day (approximately 2 mg/kg/min 2\text{ mg/kg/min} 2 mg/kg/min ) is mandatory to prevent ketosis, suppress hepatic gluconeogenesis, and spare somatic protein.

Maximum Glucose Infusion Rate (GIR): GIR (mg/kg/min) = Total Daily Dextrose (g) × 1,000 mg/g Patient Weight (kg) × 1,440 min/day \text{GIR (mg/kg/min)} = \frac{\text{Total Daily Dextrose (g)} \times 1{,}000\text{ mg/g}}{\text{Patient Weight (kg)} \times 1{,}440\text{ min/day}} GIR (mg/kg/min) = Patient Weight (kg) × 1 , 440 min/day Total Daily Dextrose (g) × 1 , 000 mg/g ​ Or for a continuous hourly infusion: GIR (mg/kg/min) = Hourly Dextrose Infusion Rate (g/hr) × 1,000 60 min/hr × Patient Weight (kg) \text{GIR (mg/kg/min)} = \frac{\text{Hourly Dextrose Infusion Rate (g/hr)} \times 1{,}000}{60\text{ min/hr} \times \text{Patient Weight (kg)}} GIR (mg/kg/min) = 60 min/hr × Patient Weight (kg) Hourly Dextrose Infusion Rate (g/hr) × 1 , 000 ​

Physiological GIR Ceilings:

In critically ill, stressed adults: 4 to 5 mg/kg/min 4\text{ to }5\text{ mg/kg/min} 4 to 5 mg/kg/min (absolute recommended ceiling).

In stable, non-stressed long-term TPN patients: up to 7 mg/kg/min 7\text{ mg/kg/min} 7 mg/kg/min .

Consequences of Exceeding GIR: When dextrose infusion exceeds hepatic oxidative capacity (~ 5 to 7 mg/kg/min 5\text{ to }7\text{ mg/kg/min} 5 to 7 mg/kg/min ), excess glucose is diverted into de novo lipogenesis in hepatocytes. This causes acute hepatic steatosis (fatty liver), marked hyperglycemia, hyperosmolar nonketotic coma, and hypercapnia . Lipogenesis from carbohydrate yields a Respiratory Quotient ( R Q RQ RQ ) of 1.2 to 1.3 1.2\text{ to }1.3 1.2 to 1.3 , generating an excessive carbon dioxide load ( VCO 2 \text{VCO}_2 VCO 2 ​ ) that precipitates respiratory acidosis and impedes weaning from mechanical ventilation.

2. Amino Acids: Crystalline L-Amino Acid Solutions

Energetic Density: Supplied as balanced crystalline solutions containing essential and non-essential amino acids, yielding 4.0 kcal/g 4.0\text{ kcal/g} 4.0 kcal/g .

Nitrogen Conversions: Grams of Nitrogen (N) = Grams of Amino Acids (Protein) 6.25 \text{Grams of Nitrogen (N)} = \frac{\text{Grams of Amino Acids (Protein)}}{6.25} Grams of Nitrogen (N) = 6.25 Grams of Amino Acids (Protein) ​

Non-Protein Calorie to Nitrogen Ratio (NPC:N): NPC:N = Total Dextrose Calories + Total Lipid Calories Total Grams of Nitrogen \text{NPC:N} = \frac{\text{Total Dextrose Calories} + \text{Total Lipid Calories}}{\text{Total Grams of Nitrogen}} NPC:N = Total Grams of Nitrogen Total Dextrose Calories + Total Lipid Calories ​

  • Normal, unstressed maintenance: 150 : 1 to 200 : 1 150:1\text{ to }200:1 150 : 1 to 200 : 1
  • Moderate catabolic stress (surgery, infection): 100 : 1 to 150 : 1 100:1\text{ to }150:1 100 : 1 to 150 : 1
  • Severe catabolic stress (major burns, severe trauma): 80 : 1 to 100 : 1 80:1\text{ to }100:1 80 : 1 to 100 : 1
  • 3. Lipids: Intravenous Lipid Emulsions (IVLE)

Energetic Density: Intravenous lipid emulsions contain vegetable oils, glycerol (added for osmotic equilibrium), and egg yolk phospholipids (added as an emulsifier). Because glycerol contributes calories, the caloric density is volume-dependent:

  • 10% IVLE: 1.1 kcal/mL 1.1\text{ kcal/mL} 1.1 kcal/mL ( 11 kcal/g 11\text{ kcal/g} 11 kcal/g of fat)
  • 20% IVLE: 2.0 kcal/mL 2.0\text{ kcal/mL} 2.0 kcal/mL ( 10 kcal/g 10\text{ kcal/g} 10 kcal/g of fat)
  • 30% IVLE: 3.0 kcal/mL 3.0\text{ kcal/mL} 3.0 kcal/mL ( 10 kcal/g 10\text{ kcal/g} 10 kcal/g of fat)

Traditional Soybean Oil Emulsions (100% Soy): High in omega-6 polyunsaturated fatty acids (linoleic acid). Excessive omega-6 metabolism generates pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4), which can suppress immune function and impair reticuloendothelial clearance.

Modern SMOF Lipid Emulsions: Multi-oil composite emulsions formulated to optimize fatty acid profiles:

S oybean oil (30%): Supplies essential linoleic and α \alpha α -linolenic acids.

M edium-Chain Triglycerides (30%): Rapidly cleared from plasma and oxidized for energy; does not burden reticuloendothelial clearance.

O live oil (25%): Rich in omega-9 monounsaturated oleic acid; neutral, resistant to lipid peroxidation.

F ish oil (15%): Rich in omega-3 fatty acids (EPA and DHA); exerts anti-inflammatory, pro-resolving, and immunoprotective effects.

Essential Fatty Acid Deficiency (EFAD): Fat-free PN induces biochemical EFAD within 1 to 3 weeks. Manifestations include dry, scaly dermatitis, alopecia, thrombocytopenia, and impaired wound healing. Diagnosis is confirmed by a triene-to-tetraene (Holman) ratio > 0.2 >0.2 > 0.2 . Prevented by providing 1 % to 2 % 1\%\text{ to }2\% 1% to 2% of total energy as linoleic acid and 0.5 % 0.5\% 0.5% as α \alpha α -linolenic acid (or 250–500 mL of 20% IVLE once or twice weekly).

Triglyceride Surveillance: Maintain serum triglycerides < 400 mg/dL <400\text{ mg/dL} < 400 mg/dL (or < 250 – 300 mg/dL <250–300\text{ mg/dL} < 250–300 mg/dL in acute pancreatitis). If serum triglycerides exceed 400 mg/dL 400\text{ mg/dL} 400 mg/dL , hold or reduce IVLE to prevent lipid-induced pancreatitis.

4. Parenteral Micronutrient Adjustments

Trace Elements in Liver and Kidney Dysfunction:

In cholestasis and biliary obstruction (elevated direct bilirubin, alkaline phosphatase), withhold copper and manganese . Both trace elements are excreted primarily via bile. Impaired excretion causes systemic accumulation, leading to copper hepatotoxicity and manganese neurotoxicity in the basal ganglia (Parkinsonian movement disorders).

In severe renal failure , withhold or monitor chromium and selenium , which are cleared by the kidneys.

Iron Omission: Iron dextran or iron sucrose is generally omitted from daily PN admixtures because iron destabilizes lipid emulsions, promotes rapid bacterial proliferation, and increases the risk of anaphylactoid reactions. Iron is infused separately when indicated.

  • PN Compounding: 2-in-1 vs. 3-in-1 Admixtures and Precipitation Hazards Parenteral Compounding Models
  • │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • [2-in-1 Formulation] [3-in-1 / TNA / AIO]
  • Dextrose + Amino acids in bag - Dextrose + Amino acids + Lipids in 1 bag
  • Lipids infused separately (piggyback) - Single infusion pump and line

- Clear solution: easy visual inspection - Milky white: OBSCURES precipitates!

  • Utilizes 0.22-micron sterilizing filter - Requires 1.2-micron filter (0.22 clogs)
  • Higher chemical stability - Risk of lipid "cracking" & creaming
  • 1. 2-in-1 Admixtures vs. 3-in-1 (Total Nutrient Admixtures - TNA)

2-in-1 Admixtures: Dextrose and amino acids are combined in a single primary infusion container, while lipids are infused separately via a secondary piggyback infusion line distal to the filter.

Advantages: Clear, translucent solution allows immediate visual inspection for particulate matter, hair, or chemical precipitates; higher chemical stability; permits in-line filtration with a 0.22-micron sterilizing filter (which retains bacteria and particulate matter).

Disadvantages: Requires two separate infusion lines/pumps, increasing nursing workload and the number of catheter violations.

3-in-1 Admixtures (Total Nutrient Admixture [TNA] / "All-in-One"): Dextrose, amino acids, and lipids are combined in a single container.

Advantages: Single container and single pump simplify administration, improve patient mobility, and reduce catheter manipulation.

Disadvantages: Milky-white, opaque emulsion completely obscures visual detection of particulate matter and precipitates ; less stable; requires a 1.2-micron filter (a 0.22-micron filter would become clogged by lipid droplet particles); increased risk of emulsion destabilization.

2. Lipid Emulsion Destabilization: "Creaming" vs. "Cracking"

Creaming: Lipid droplets rise to the surface of the admixture, forming a translucent, milky layer. It is reversible with gentle inversion.

Cracking: Complete, irreversible destruction of the emulsion. Lipid droplets fuse together, forming a visible, free amber oil slick on the surface. Infusing a cracked emulsion is fatal , as large oil droplets ( > 5 μ m >5\ \mu\text{m} > 5 μ m ) cause acute pulmonary capillary microembolism. Factors that trigger cracking include acidic pH ( < 5.0 <5.0 < 5.0 ) and high concentrations of trivalent ( F e 3 + Fe^{3+} F e 3 + ) or divalent ( C a 2 + , M g 2 + Ca^{2+}, Mg^{2+} C a 2 + , M g 2 + ) cations that neutralize the negative zeta-potential of phospholipid droplets.

3. Calcium-Phosphate Precipitation Hazards

Insoluble dibasic calcium phosphate ( C a H P O 4 CaHPO_4 C a H P O 4 ​ ) precipitate formation in PN solutions is a major physical-chemical hazard that can cause fatal microvascular pulmonary embolism. Compounding pharmacists and clinical dietitians must manage the factors governing solubility:

pH of the Admixture: The most critical determinant. Monobasic phosphate ( H 2 P O 4 − H_2PO_4^- H 2 ​ P O 4 − ​ ) is highly soluble, whereas dibasic phosphate ( H P O 4 2 − HPO_4^{2-} H P O 4 2 − ​ ) is insoluble and rapidly precipitates with free calcium. Alkaline pH shifts equilibrium toward the insoluble dibasic form ( H P O 4 2 − HPO_4^{2-} H P O 4 2 − ​ ) . Acidic pH preserves the soluble monobasic form.

Choice of Calcium Salt: Calcium gluconate is always preferred over calcium chloride . Calcium chloride dissociates rapidly and completely, yielding high concentrations of free reactive C a 2 + Ca^{2+} C a 2 + . Calcium gluconate has a lower dissociation constant, releasing ionic calcium slowly and minimizing precipitation risk.

Amino Acid Concentration: Amino acids act as chemical buffers and weak chelators; high amino acid concentrations ( > 2.5 % >2.5\% > 2.5% ) bind calcium and keep it in solution, inhibiting precipitation.

Ambient Temperature: Precipitation is an endothermic reaction . Warming a PN bag to room or body temperature promotes precipitation. A clear refrigerated solution may precipitate once hung at room temperature.

Compounding Sequence: Always add phosphate early to the dextrose/amino acid base, agitate thoroughly, and add calcium gluconate near the end of compounding.